OBJECTIVES: To determine long-term efficacy of intravesical @entity1138 ( @entity1139 ) versus bacille Calmette-Gu  rin (BCG) in @entity1 with superficial @entity150 with regard to recurrences and progression. METHODS: @entity1 with superficial @entity150 (pTa, @entity2558 , pTis) were treated with intravesical @entity1139 (30 mg, weekly for 4 weeks, and thereafter monthly for 5 months) or BCG (weekly for 6 weeks). RESULTS: Three hundred forty-four @entity1 were eligible (171 in the BCG group, 173 in the @entity1139 group). The median follow-up was 7.2 years. @entity137 was not significantly different between the two treatment groups. Efficacy of the two treatment policies was similar with regard to @entity5 recurrence. With regard to progression to invasive disease, @entity1139 was more effective than BCG in @entity1 without @entity189 in situ (CIS) (P = 0.006). CONCLUSIONS: We can confirm the conclusions of other studies that intravesical treatment with 30 mg of @entity1139 remains an effective treatment option that can also be used in high-risk @entity1 . Like others, we could not confirm that a 6-week course of BCG is more effective in the prevention of @entity5 progression. Of the 33 @entity1 with @entity5 progression after intravesical therapy, 20 died of @entity150 , confirming that @entity5 progression after intravesical therapy carries a poor prognosis. In this study the difference in toxicity between BCG and @entity1139 was not significant. When comparing studies with @entity1139 and BCG, differences in treatment schedule and/or @entity1 selection should be kept in mind.

Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Gu  rin-RIVM and @entity1138 in superficial XXXX . EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of @entity5 Collaborative Group.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity2558 :: ('58492', 'Gene') :: ['pT1'] @entity137 :: ('MESH:D064420', 'Disease') :: ['Toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity1138 :: ('MESH:D016685', 'Chemical') :: ['mitomycin C'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma'] @entity1139 :: ('CHEBI:27504', 'Chemical') :: ['MMC'] @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancer']
@entity150 :: (MESH:D001749,Disease) :: ['bladder cancer']
